{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T21:57:03Z","timestamp":1795039023846,"version":"4.10.2"},"reference-count":45,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Many hematologic malignancies are not curable with chemotherapy and require novel therapeutic approaches. Chimeric antigen receptor (CAR) T-cell therapy is 1 such approach that involves the transfer of T cells engineered to express CARs for a specific cell-surface antigen. CD38 is a validated tumor antigen in multiple myeloma (MM) and T-cell acute lymphoblastic leukemia (T-ALL) and is also overexpressed in acute myeloid leukemia (AML). Here, we developed human CD38-redirected T cells (CART-38) as a unified approach to treat 3 different hematologic malignancies that occur across the pediatric-to-adult age spectrum. Importantly, CD38 expression on activated T cells did not impair CART-38 cells expansion or in\u00a0vitro function. In xenografted mice, CART-38 mediated the rejection of AML, T-ALL, and MM cell lines and primary samples and prolonged survival. In a xenograft model of normal human hematopoiesis, CART-38 resulted in the expected reduction of hematopoietic progenitors, which warrants caution and careful monitoring of this potential toxicity when translating this new immunotherapy into the clinic. Deploying CART-38 against multiple CD38-expressing malignancies is significant because it expands the potential for this novel therapy to affect diverse patient populations.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007059","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T10:44:08Z","timestamp":1683888248000},"page":"4418-4430","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":72,"title":["CD38 as a pan-hematologic target for chimeric antigen receptor T\u00a0cells"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8403-1570","authenticated-orcid":false,"given":"Tina","family":"Glisovic-Aplenc","sequence":"first","affiliation":[{"name":"1Division of Oncology, Center for Childhood Cancer Research, The Children\u2019s Hospital of Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8005-3836","authenticated-orcid":false,"given":"Caroline","family":"Diorio","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Center for Childhood Cancer Research, The Children\u2019s Hospital of Philadelphia, PA"},{"name":"2Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Chukinas","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Center for Childhood Cancer Research, The Children\u2019s Hospital of Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3824-1611","authenticated-orcid":false,"given":"Kimberly","family":"Veliz","sequence":"additional","affiliation":[{"name":"3Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA"},{"name":"4Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Shestova","sequence":"additional","affiliation":[{"name":"3Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA"},{"name":"4Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Shen","sequence":"additional","affiliation":[{"name":"3Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA"},{"name":"4Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4538-957X","authenticated-orcid":false,"given":"Selene","family":"Nunez-Cruz","sequence":"additional","affiliation":[{"name":"3Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffaney L.","family":"Vincent","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Center for Childhood Cancer Research, The Children\u2019s Hospital of Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Miao","sequence":"additional","affiliation":[{"name":"3Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Milone","sequence":"additional","affiliation":[{"name":"3Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0241-3557","authenticated-orcid":false,"given":"Carl H.","family":"June","sequence":"additional","affiliation":[{"name":"3Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7373-8987","authenticated-orcid":false,"given":"David T.","family":"Teachey","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Center for Childhood Cancer Research, The Children\u2019s Hospital of Philadelphia, PA"},{"name":"2Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1327-1662","authenticated-orcid":false,"given":"Sarah K.","family":"Tasian","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Center for Childhood Cancer Research, The Children\u2019s Hospital of Philadelphia, PA"},{"name":"2Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7482-5644","authenticated-orcid":false,"given":"Richard","family":"Aplenc","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Center for Childhood Cancer Research, The Children\u2019s Hospital of Philadelphia, PA"},{"name":"2Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7946-7778","authenticated-orcid":false,"given":"Saar","family":"Gill","sequence":"additional","affiliation":[{"name":"3Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA"},{"name":"4Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,8,11]]},"reference":[{"issue":"8","key":"2023082114543607900_bib1","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"2023082114543607900_bib2","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2023082114543607900_bib3","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"issue":"18","key":"2023082114543607900_bib4","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1200\/JCO.2013.52.8562","article-title":"International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed\/refractory acute myeloid leukemia","volume":"32","author":"Roboz","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2023082114543607900_bib5","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/1744666X.2020.1732819","article-title":"Harnessing immunotherapy for pediatric T-cell malignancies","volume":"16","author":"Diorio","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"2023082114543607900_bib6","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S1470-2045(19)30031-2","article-title":"Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia","volume":"20","author":"Teachey","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"2023082114543607900_bib7","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.tips.2018.02.001","article-title":"The pharmacology of CD38\/NADase: an emerging target in cancer and diseases of aging","volume":"39","author":"Chini","year":"2018","journal-title":"Trends Pharmacol Sci"},{"issue":"9","key":"2023082114543607900_bib8","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/2159-8290.CD-17-1033","article-title":"CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1\/PD-L1 blockade","volume":"8","author":"Chen","year":"2018","journal-title":"Cancer Discov"},{"issue":"19","key":"2023082114543607900_bib9","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1158\/0008-5472.CAN-14-3639","article-title":"CD38-expressing myeloid-derived suppressor cells promote tumor growth in a murine model of esophageal cancer","volume":"75","author":"Karakasheva","year":"2015","journal-title":"Cancer Res"},{"issue":"1","key":"2023082114543607900_bib10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back to the future","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood"},{"issue":"9","key":"2023082114543607900_bib11","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","article-title":"Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia","volume":"131","author":"Bride","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2023082114543607900_bib12","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41375-019-0548-z","article-title":"Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell\/CD19\/CD22-negative acute lymphoblastic leukemia","volume":"34","author":"Ofran","year":"2020","journal-title":"Leukemia"},{"issue":"3","key":"2023082114543607900_bib13","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.3324\/haematol.2018.192757","article-title":"CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia","volume":"104","author":"Naik","year":"2019","journal-title":"Haematologica"},{"issue":"6","key":"2023082114543607900_bib14","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2023082114543607900_bib15","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/jpet.119.256602","article-title":"A\u00a0reduction in B, T, and Natural Killer Cells expressing CD38 by TAK-079 inhibits the induction and progression of collagen-induced arthritis in cynomolgus monkeys","volume":"370","author":"Korver","year":"2019","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"5","key":"2023082114543607900_bib16","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1016\/S2352-3026(19)30249-2","article-title":"MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial","volume":"7","author":"Raab","year":"2020","journal-title":"Lancet Haematol"},{"issue":"8","key":"2023082114543607900_bib17","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in\u00a0vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol Ther"},{"issue":"15","key":"2023082114543607900_bib18","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","article-title":"Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T\u00a0cells","volume":"123","author":"Gill","year":"2014","journal-title":"Blood"},{"issue":"17","key":"2023082114543607900_bib19","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1182\/blood-2016-08-736041","article-title":"Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia","volume":"129","author":"Tasian","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2023082114543607900_bib20","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/leu.2015.52","article-title":"CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia","volume":"29","author":"Kenderian","year":"2015","journal-title":"Leukemia"},{"issue":"9","key":"2023082114543607900_bib21","doi-asserted-by":"crossref","first-page":"1-12","DOI":"10.1136\/jitc-2021-003149","article-title":"Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design","volume":"9","author":"Qin","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2023082114543607900_bib22","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0091-679X(04)75020-7","article-title":"Detection of T-cell degranulation: CD107a and b","volume":"75","author":"Betts","year":"2004","journal-title":"Methods Cell Biol"},{"issue":"6","key":"2023082114543607900_bib23","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/cyto.a.20887","article-title":"Development and application of a multiplexable flow cytometry-based assay to quantify cell-mediated cytolysis","volume":"77","author":"Cao","year":"2010","journal-title":"Cytometry A"},{"issue":"7","key":"2023082114543607900_bib24","first-page":"737","article-title":"Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma","volume":"32","author":"Mihara","year":"2009","journal-title":"J\u00a0Immunother"},{"issue":"8","key":"2023082114543607900_bib25","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jgg.2019.06.007","article-title":"Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells","volume":"46","author":"Gao","year":"2019","journal-title":"J\u00a0Genet Genomics"},{"issue":"10","key":"2023082114543607900_bib26","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med"},{"issue":"12","key":"2023082114543607900_bib27","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMoa1106968","article-title":"Clonal architecture of secondary acute myeloid leukemia","volume":"366","author":"Walter","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023082114543607900_bib28","doi-asserted-by":"crossref","first-page":"5280","DOI":"10.1038\/s41467-018-07584-1","article-title":"Age-specific biological and molecular profiling distinguishes paediatric from adult acute myeloid leukaemias","volume":"9","author":"Chaudhury","year":"2018","journal-title":"Nat Commun"},{"issue":"6","key":"2023082114543607900_bib29","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"issue":"6","key":"2023082114543607900_bib30","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"issue":"7","key":"2023082114543607900_bib31","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2023082114543607900_bib32","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B\u00a0cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J\u00a0Clin Invest"},{"issue":"5","key":"2023082114543607900_bib33","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.4049\/jimmunol.160.5.2238","article-title":"CD38 functions are regulated through an internalization step","volume":"160","author":"Funaro","year":"1998","journal-title":"J\u00a0Immunol"},{"issue":"10","key":"2023082114543607900_bib34","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1021\/acs.molpharmaceut.8b00584","article-title":"Anti-multiple myeloma activity of nanobody-based anti-cd38 chimeric antigen receptor T cells","volume":"15","author":"An","year":"2018","journal-title":"Mol Pharm"},{"issue":"1","key":"2023082114543607900_bib35","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/sj.leu.2402785","article-title":"CD38 expression by hematopoietic stem cells of newborn and juvenile mice","volume":"17","author":"Higuchi","year":"2003","journal-title":"Leukemia"},{"issue":"5","key":"2023082114543607900_bib36","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3324\/haematol.2015.137620","article-title":"Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma","volume":"101","author":"Drent","year":"2016","journal-title":"Haematologica"},{"issue":"12","key":"2023082114543607900_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/cti.2016.73","article-title":"All-trans retinoic acid enhances cytotoxic effect of T cells with an anti-CD38 chimeric antigen receptor in acute myeloid leukemia","volume":"5","author":"Yoshida","year":"2016","journal-title":"Clin Transl Immunology"},{"issue":"6464","key":"2023082114543607900_bib38","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/367645a0","article-title":"A\u00a0cell initiating human acute myeloid leukaemia after transplantation into SCID mice","volume":"367","author":"Lapidot","year":"1994","journal-title":"Nature"},{"issue":"1","key":"2023082114543607900_bib39","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ccr.2010.12.012","article-title":"Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia","volume":"19","author":"Goardon","year":"2011","journal-title":"Cancer Cell"},{"issue":"10","key":"2023082114543607900_bib40","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1182\/blood-2009-02-206565","article-title":"Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction","volume":"115","author":"Taussig","year":"2010","journal-title":"Blood"},{"issue":"10","key":"2023082114543607900_bib41","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.3324\/haematol.2018.197640","article-title":"Daratumumab for relapsed\/refractory Philadelphia-positive acute lymphoblastic leukemia","volume":"103","author":"Ganzel","year":"2018","journal-title":"Haematologica"},{"issue":"8","key":"2023082114543607900_bib42","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood.2019000904","article-title":"Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia","volume":"134","author":"Vogiatzi","year":"2019","journal-title":"Blood"},{"issue":"suppl 16","key":"2023082114543607900_bib43","first-page":"10001-10001","article-title":"Efficacy and safety of daratumumab (DARA) in pediatric and young adult patients (pts) with relapsed\/refractory\u00a0T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL): Results from the phase 2 DELPHINUS study","volume":"40","author":"Hogan","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"2023082114543607900_bib44","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1146\/annurev-immunol-032712-095921","article-title":"Human hemato-lymphoid system mice: current use and future potential for medicine","volume":"31","author":"Rongvaux","year":"2013","journal-title":"Annu Rev Immunol"},{"issue":"8","key":"2023082114543607900_bib45","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.ymthe.2017.04.024","article-title":"A\u00a0rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization","volume":"25","author":"Drent","year":"2017","journal-title":"Mol Ther"}],"updated-by":[{"DOI":"10.1182\/bloodadvances.2024014719","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000}}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/16\/4418\/2072810\/blooda_adv-2022-007059-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/16\/4418\/2072810\/blooda_adv-2022-007059-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T10:55:06Z","timestamp":1692615306000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/16\/4418\/495779\/CD38-as-a-pan-hematologic-target-for-chimeric"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,11]]},"references-count":45,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2023,8,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007059","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,11]]}}}